跳转至内容
Merck
CN
  • Patient education and self-care for the management of jaw pain upon awakening: a randomized controlled clinical trial comparing the effectiveness of adding pharmacologic treatment with cyclobenzaprine or tizanidine.

Patient education and self-care for the management of jaw pain upon awakening: a randomized controlled clinical trial comparing the effectiveness of adding pharmacologic treatment with cyclobenzaprine or tizanidine.

Journal of oral & facial pain and headache (2014-05-14)
Francisco Guedes Pereira Alencar, Patricia Gabriela Viana, Camila Zamperini, Anne Becker
摘要

To compare the effectiveness of adding cyclobenzaprine, tizanidine, or placebo to patient education and a self-care management program for patients with myofascial pain and specifically presenting with jaw pain upon awakening. Forty-five patients with a diagnosis of myofascial pain based on the guidelines of the American Academy of Orofacial Pain participated in this 3-week study. The subjects were randomly assigned into one of three groups: placebo group, TZA group (tizanidine 4 mg), or CYC group (cyclobenzaprine 10 mg). Patients were evaluated for changes in pain intensity, frequency, and duration by using the modified Severity Symptoms Index and changes in sleep quality with the use of the Pittsburgh Sleep Quality Index. Data were analyzed by ANOVA and post-hoc or nonparametric statistical tests as appropriate. All three groups had a reduction in pain symptoms and improvement of sleep quality based on a comparison of pretreatment and treatment scores. However, no significant differences among the groups were observed at the posttreatment evaluation. The use of tizanidine or cyclobenzaprine in addition to self-care management and patient education was not more effective than placebo for the management of patients with myofascial jaw pain upon awakening.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
布洛芬, ≥98% (GC)
Supelco
布洛芬, Pharmaceutical Secondary Standard; Certified Reference Material
USP
布洛芬, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
( S )-(+)-布洛芬, ReagentPlus®, 99%
Sigma-Aldrich
盐酸阿米替林 盐酸盐, ≥98% (TLC), powder
布洛芬, European Pharmacopoeia (EP) Reference Standard
Supelco
布洛芬
Supelco
布洛芬 钠盐, ≥98% (GC)
Supelco
盐酸阿米替林标准液 盐酸盐 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
布洛芬, European Pharmacopoeia (EP) Reference Standard
Supelco
Ibuprofen 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
布洛芬, meets USP testing specifications
Supelco
盐酸阿米替林, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Cyclobenzaprine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
环苯扎林 盐酸盐
USP
盐酸阿米替林 盐酸盐, United States Pharmacopeia (USP) Reference Standard
Supelco
可乐定标准液 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
环苯扎林 盐酸盐, European Pharmacopoeia (EP) Reference Standard
盐酸阿米替林 盐酸盐, European Pharmacopoeia (EP) Reference Standard